Trametinib

Current understanding

To be populated as evidence accumulates.

Evidence log

• 2026-07-20 — Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia: Phase II trial evaluating trametinib monotherapy in relapsed/refractory JMML to test MEK inhibition of the RAS–MAPK axis in this rare pediatric MDS/MPN overlap disease. (novelty: 3)
• 2026-09-04 — A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia: Being evaluated in a Phase I/II trial combined with azacitidine (± fludarabine/cytarabine for high-risk) in newly diagnosed JMML, leveraging MEK inhibition against the RAS–MAPK axis central to JMML biology. (novelty: 3)

Open questions

Related